Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NUVB Nuvation Bio, Inc.

Market Closed 07-31 16:00:00 EDT

6.33

-0.37

-5.52%

盘后6.24

-0.09-1.42%

19:40 EDT

High6.69	Low6.30	Vol4.89M
Open6.68	D1 Closing6.70	Amplitude5.90%
Mkt Cap2.20B	Tradable Cap1.61B	Total Shares347.60M
T/O31.18M	T/O Rate1.92%	Tradable Shares255.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NUVB","market":"US","secType":"STK","nameCN":"Nuvation Bio, Inc.","latestPrice":6.33,"timestamp":1785528000000,"preClose":6.7,"halted":0,"volume":4891203,"hourTrading":{"tag":"盘后","latestPrice":6.24,"preClose":6.33,"latestTime":"19:40 EDT","volume":140959,"amount":892194.7288,"timestamp":1785541214519,"change":-0.09,"changeRate":-0.014218,"amplitude":0.018957},"delay":0,"changeRate":-0.05522388059701494,"floatShares":254999999,"shares":347597289,"eps":-0.424745,"marketStatus":"Market Closed","change":-0.37,"latestTime":"07-31 16:00:00 EDT","open":6.68,"high":6.69,"low":6.295,"amount":31182193.4024349,"amplitude":0.058955,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.424745,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785744000000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":6.7,"preHourTrading":{"tag":"盘前","latestPrice":6.7276,"preClose":6.7,"latestTime":"09:24 EDT","volume":3184,"amount":21414.657456,"timestamp":1785504255364,"change":0.0276,"changeRate":0.004119,"amplitude":0.022388},"postHourTrading":{"tag":"盘后","latestPrice":6.24,"preClose":6.33,"latestTime":"19:40 EDT","volume":140959,"amount":892194.7288,"timestamp":1785541214519,"change":-0.09,"changeRate":-0.014218,"amplitude":0.018957},"volumeRatio":0.8205012664019758,"impliedVol":1.1562,"impliedVolPercentile":0.498},"requestUrl":"/m/hq/s/NUVB","defaultTab":"news","newsList":[{"id":"2654010979","title":"Nuvation Bio is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2654010979","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654010979?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:30","pubTimestamp":1785155400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NUVB/analyst-ratings(END) Dow Jones NewswiresJuly 27, 2026 08:30 ET","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654010820","title":"Nuvation Bio Inc. : H.c. Wainwright Raises Target Price to $21 from $17","url":"https://stock-news.laohu8.com/highlight/detail?id=2654010820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654010820?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:20","pubTimestamp":1785154826,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nAZN4TA4C6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653726072","title":"Nuvation Bio Price Target Maintained with a $11.00/share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2653726072","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653726072?lang=en_us&edition=fundamental","pubTime":"2026-07-23 22:32","pubTimestamp":1784817120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NUVB/analyst-ratings(END) Dow Jones NewswiresJuly 23, 2026 10:32 ET","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653026798","title":"Nuvation Bio Schedules Q2 2026 Results Call, Business Update Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2653026798","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653026798?lang=en_us&edition=fundamental","pubTime":"2026-07-23 04:13","pubTimestamp":1784751203,"startTime":"0","endTime":"0","summary":"Nuvation Bio schedules Q2 2026 results call, business update webcastNuvation Bio schedules Q2 2026 results conference call, webcast for Aug. 6, 2026 at 8:00 a.m. ET.Live webcast registration available","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL5yng7R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653798617","title":"Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653798617","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653798617?lang=en_us&edition=fundamental","pubTime":"2026-07-23 04:05","pubTimestamp":1784750702,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUABXKFG0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653764206","title":"Nuvation Bio's Safusidenib Clinical Program, Ibtrozi Opportunity Create Favorable Setup, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2653764206","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653764206?lang=en_us&edition=fundamental","pubTime":"2026-07-23 00:52","pubTimestamp":1784739163,"startTime":"0","endTime":"0","summary":"Nuvation Bio's (NUVB) leadership showed \"significant excitement\" around the Safusidenib clinical program, with strong recent data and new trials expected to demonstrate the company's commitment to the","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653764564","title":"Nuvation Bio (NUVB) Could Be 48% Undervalued As Safusidenib Data Strengthens Its Case","url":"https://stock-news.laohu8.com/highlight/detail?id=2653764564","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653764564?lang=en_us&edition=fundamental","pubTime":"2026-07-22 21:32","pubTimestamp":1784727126,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) is in focus after updated long term Phase 2 and Phase 3 data for safusidenib in grade 2 IDH1-mutant glioma showed strong response rates and a consistent safety profile.\nSee our latest analysis for Nuvation Bio.\nThe positive safusidenib data arrives as Nuvation Bio’s share price has climbed in the short term, with a 1-month share price return of 15.65% and a 3-month gain of 25.59%. However, the year-to-date share price is still down 25.06%, while the 1-year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/nuvation-bio-nuvb-could-be-48-undervalued-as-safusidenib-dat","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/nuvation-bio-nuvb-could-be-48-undervalued-as-safusidenib-dat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653248065","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2653248065","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653248065?lang=en_us&edition=fundamental","pubTime":"2026-07-21 03:06","pubTimestamp":1784574403,"startTime":"0","endTime":"0","summary":"Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index shedding 1.1% and the State Street Health Care Select Sector SPDR ETF  decreasing 0.8%.The iShares Biotechnology ETF  fell 1.1%.In corporate news, Nuvation Bio  shares jumped past 8% after it said Monday that follow-up data from a phase 2 trial of safusidenib in people with chemotherapy and radiotherapy-naive grade 2 IDH1-mutant glioma showed \"durable\" efficacy, with objective response rate of 51.9% and 36-month progression-free survival rate of 79.1%.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4581","HCSG","LU0128526141.USD","BK4585","BK4588","XLV","LU0029874061.USD","XBI","BK4007","LABU","IBB","BK4137","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653212000","title":"U.S. Stocks on the Move-yum Brands, AMD, Nuvation Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2653212000","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653212000?lang=en_us&edition=fundamental","pubTime":"2026-07-21 00:10","pubTimestamp":1784563839,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Yum Brands, AMD, Nuvation BioWorkspace search string for individual stock moves:STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nL6N43M0S5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089985449.USD","LU0823421416.USD","LU2360106780.USD","SG9999001424.SGD","IE00BMPRXQ63.HKD","SMH","LU1880398554.USD","IE00B5949003.HKD","LU0889565833.HKD","BK4612","BK4575","USXF","CHAT","LU0889566641.SGD","IE0004445239.USD","AMDL","TEK","AMDY","LU0048584097.USD","AMDS","LU1989764664.SGD","LU0127658192.USD","ARTY","LU2458330169.SGD","LU1989772923.USD","XNTK","LU0082616367.USD","LU0274383776.USD","LU1803068979.SGD","YUM","LU1861559042.SGD","LU2361044949.HKD","LU0133085943.USD","LU0786609619.USD","BK4605","LU0792757196.USD","IE00BQXX3D17.EUR","NUVB","LU1242518857.USD","IE00BKVL7J92.USD","LU0198837287.USD","LU2462591350.SGD","IE00BMPRXR70.SGD","LU2250418816.HKD","FTXL","LU1852331112.SGD","SMHX","FAI","LU0174119429.USD","LU1242518931.SGD","LU1989764748.USD","BK4566","IE00BQXX3C00.GBP","LU1316542783.SGD","BK4512","LU2506951875.HKD","BK4504","LU0081259029.USD","LU2458330243.SGD","BK4585","BK4209","LU0719512351.SGD","QQQA","LU0823434740.USD","LU1064131342.USD","WISE","IE00BMPRXN33.USD","DAMD","WUGI","LU0056508442.USD","LU2355687059.USD","LU2108987350.USD","PSI","LU0979878070.USD","LU0390134368.USD","AMDG","LU1303367103.USD","IETC","IE0009356076.USD","CNAV","LU2133065610.SGD","BAI","LU2054465674.USD","LU0251132253.USD","TRFK","TTEQ","BK4007","IE00BZ1G4Q59.USD","LU2931357623.SGD","LU0109392836.USD","AMUU","IE00BQXX3F31.USD","BK4588","LU2361044865.SGD","LU1861558580.USD","LU2242649171.HKD","CHPS","LU0823417653.USD","LU2506952170.USD","AMDD","AMD","BK4573","LEGR","LU1951198990.SGD","LU1923623000.USD","AMDU","SOXX","LU1988902786.USD","LU2264538146.SGD","IE0001KFT4U8.USD","LU1989772840.SGD","LU1267930813.SGD","SGXZ81514606.USD","AMYY","AMDW","BK4529","LU0823421333.USD","AIS","AIQ","LU2247934214.USD","LU2098885051.SGD","SGXZ99366536.SGD","SOXY","LU2265009873.SGD","IE00B1BXHZ80.USD","BK4141","LU0823417737.USD","BK4614","LU1951200564.SGD","BK4554","LU2361045086.USD","LU0210536198.USD","BK4534","LU2506951958.HKD","LU2461242641.AUD","ILDR","LU0950375773.USD","LU1804176565.USD","BK4532","LU2860962120.EUR","BK4543","SGXZ51526630.SGD","LU2896262040.SGD","LU0823434583.USD","LU0642271901.SGD","LU2506952097.USD","LU1880398471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652214091","title":"RBC looks for Nuvation shares to appreciate as safusidenib data builds","url":"https://stock-news.laohu8.com/highlight/detail?id=2652214091","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652214091?lang=en_us&edition=fundamental","pubTime":"2026-07-20 23:05","pubTimestamp":1784559917,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Leonid Timashev notes Nuvation Bio (NUVB) has reported 40-month follow-up data for their glioma drug – safusidenib, which is a ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rbc-looks-for-nuvation-shares-to-appreciate-as-safusidenib-data-builds-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rbc-looks-for-nuvation-shares-to-appreciate-as-safusidenib-data-builds-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128525929.USD","NUVB","LU0310800379.SGD","BK4007","LU1267930573.SGD","BK4207","LU0708994859.HKD","GSIB","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652219982","title":"Nuvation Bio Rises as Brain Cancer Drug Data Spur Expansion of Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2652219982","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652219982?lang=en_us&edition=fundamental","pubTime":"2026-07-20 21:51","pubTimestamp":1784555504,"startTime":"0","endTime":"0","summary":"BUZZ-Nuvation Bio rises as brain cancer drug data spur expansion of studies** Shares of cancer treatment firm Nuvation BioNUVB.Nrise 5.3% to $6.11** Co says its experimental brain cancerdrug, safusidenib,showed a 52% confirmed response rate in patients with IDH1-mutant glioma, a common type of brain tumor caused by a gene mutation** Says nearly 80% of patients were alive without their disease worsening three years after starting treatment in a Japanese mid-stage study** Co will start a late-stage study outside the U.S. in about 140 newly diagnosed patients who have not received chemotherapy or radiation** Says safusidenib's safety profile remained manageable** Including session's move, stock down ~32% YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nL4N43M0YE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652139792","title":"Nuvation Bio Posts Corporate Deck Highlighting Ibtrozi ROS1+ NSCLC Launch, Safusidenib IDH1 Glioma Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2652139792","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652139792?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:18","pubTimestamp":1784549881,"startTime":"0","endTime":"0","summary":"Nuvation Bio posts corporate deck highlighting IBTROZI ROS1+ NSCLC launch, safusidenib IDH1 glioma programNuvation Bio highlighted IBTROZI (taletrectinib) as a commercial driver, with U.S. net product","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDLbYHb77:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652117213","title":"Nuvation Bio announces data from the Phase 2 J201 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2652117213","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652117213?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:05","pubTimestamp":1784549116,"startTime":"0","endTime":"0","summary":"Nuvation Bio (NUVB) announced updated positive long-term follow-up data from the Phase 2, or J201, study of safusidenib in patients with chemothera...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nuvation-bio-announces-data-from-the-phase-2-j201-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nuvation-bio-announces-data-from-the-phase-2-j201-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652213810","title":"Nuvation Bio Reports Updated Phase 2 Safusidenib Data, Expands Idh1-mutant Glioma Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2652213810","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652213810?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:03","pubTimestamp":1784549015,"startTime":"0","endTime":"0","summary":"Nuvation Bio reports updated Phase 2 safusidenib data, expands IDH1-mutant glioma studiesNuvation Bio posted an announcement on updated Phase 2 data for safusidenib in grade 2 IDH1-mutant glioma.Confirmed ORR 51.9%; 36-month PFS rate 79.1%; median follow-up 38.8 months; median PFS not reached.Clinical program expansion outlined, including a new ex-U.S. Phase 3 study G307 ().New U.S. Phase 2 study G209 targets patients progressing on vorasidenib ().Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via PR Newswire  on July 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL3D0NYn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652187272","title":"Nuvation Bio - Reports 52% Confirmed Objective Response Rate in Phase 2 Safusidenib Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2652187272","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652187272?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:00","pubTimestamp":1784548828,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nFWN43M05C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651931541","title":"Analysts’ Top Healthcare Picks: Argenx Se (ARGX), Nuvation Bio (NUVB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651931541","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651931541?lang=en_us&edition=fundamental","pubTime":"2026-07-13 13:30","pubTimestamp":1783920609,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Argenx Se (ARGX) and Nuvation Bio (NUVB) with bullis...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-argenx-se-argx-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-argenx-se-argx-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","HCSG","LU0320765992.SGD","BK4585","IBB","IE0034235188.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU1983260115.SGD","IE00B4R5TH58.HKD","NUVB","XBI","LABU","LU0128526141.USD","IE00BJT1NW94.SGD","LU0029874061.USD","IE0009355771.USD","LU2324357040.USD","BK4505","BK4007","IE0002141913.USD","BK4581","ARGX","BK4137","FMED","XLV","LU0109394709.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649980357","title":"Nuvation Bio is Maintained at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2649980357","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649980357?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:36","pubTimestamp":1783427760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NUVB/analyst-ratings(END) Dow Jones NewswiresJuly 07, 2026 08:36 ET","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649267104","title":"Nuvation Bio Prices Upsized USD 287.5 Million Convertible Senior Notes After Full Greenshoe Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=2649267104","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649267104?lang=en_us&edition=fundamental","pubTime":"2026-07-07 05:10","pubTimestamp":1783372239,"startTime":"0","endTime":"0","summary":"Nuvation Bio prices upsized USD 287.5 million convertible senior notes after full greenshoe exerciseNuvation Bio priced USD 287.5 million of 0.75% Convertible Senior Notes due 2032 following full exer","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL9pdR1K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649671052","title":"Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2649671052","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649671052?lang=en_us&edition=fundamental","pubTime":"2026-07-07 05:10","pubTimestamp":1783372214,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nTUA5MJCKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648056730","title":"Nuvation Bio Plans Offering of $200 Million Convertible Senior Notes Due 2032","url":"https://stock-news.laohu8.com/highlight/detail?id=2648056730","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648056730?lang=en_us&edition=fundamental","pubTime":"2026-07-01 05:18","pubTimestamp":1782854281,"startTime":"0","endTime":"0","summary":"Nuvation Bio plans offering of $200 million convertible senior notes due 2032Nuvation Bio launched an underwritten offering of USD 200 million Convertible Senior Notes due 2032.Underwriters received a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL9CDRbw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.014},{"period":"1month","weight":0.1679},{"period":"3month","weight":0.4098},{"period":"6month","weight":0.208},{"period":"1year","weight":1.6822},{"period":"ytd","weight":-0.2935}],"compareEarnings":[{"period":"1week","weight":0.011},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0366},{"period":"6month","weight":0.0796},{"period":"1year","weight":0.1819},{"period":"ytd","weight":0.0955}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung , M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco .","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.099824},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.044723},{"month":3,"riseRate":0.5,"avgChangeRate":0.083814},{"month":4,"riseRate":0.5,"avgChangeRate":0.010626},{"month":5,"riseRate":0.666667,"avgChangeRate":0.014611},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.044383},{"month":7,"riseRate":0.666667,"avgChangeRate":0.074},{"month":8,"riseRate":0.6,"avgChangeRate":0.013694},{"month":9,"riseRate":0.5,"avgChangeRate":-0.038205},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.016548},{"month":11,"riseRate":0.5,"avgChangeRate":0.163132},{"month":12,"riseRate":0.666667,"avgChangeRate":0.061496}],"exchange":"NYSE","name":"Nuvation Bio, Inc.","nameEN":"Nuvation Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nuvation Bio, Inc.(NUVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nuvation Bio, Inc.,NUVB,Nuvation Bio, Inc.股票,Nuvation Bio, Inc.股票老虎,Nuvation Bio, Inc.股票老虎国际,Nuvation Bio, Inc.行情,Nuvation Bio, Inc.股票行情,Nuvation Bio, Inc.股价,Nuvation Bio, Inc.股市,Nuvation Bio, Inc.股票价格,Nuvation Bio, Inc.股票交易,Nuvation Bio, Inc.股票购买,Nuvation Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nuvation Bio, Inc.(NUVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nuvation Bio, Inc.(NUVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}